The Antiangiogenic Activity of Anti-IL-6 and Anti-IL-8 in the Tumor Microenvironment of Breast Cancer (Preclinical Study)

Document Type : Original Article

Authors

1 Department of Immunology and Allergy, Medical Research Institute, Alexandria University, Egypt

2 National Institute of Oceanography and Fisheries, Central Laboratories Unit, Alexandria Egypt.

3 Department of Surgery, Medical Research Institute, Alexandria University, Alexandria, Egypt

4 Microbiology & Immunology Department, Faculty of Pharmacy, Pharos university in Alexandria, Alexandria , Egypt

Abstract

The tumor microenvironment of breast cancer is considered a vibrant, multifactorial milieu that contains different cell subsets that shape the tumor fate. In addition, cytokines play a vital role within the tumor microenvironment, where different cytokines can promote inflammation, angiogenesis, and immune suppression. Interleukin-8 (IL-8) and Interleukin-6 (IL-6) are two of the most important cytokines that aid tumor progression and metastasis. Thus, this study aimed to compare the anti-angiogenic actions of neutralizing antibodies against IL-8 and IL-6. Tumor tissues from 30 patients having mastectomy supplemented with either monoclonal neutralizing antibodies against IL-8 or IL-6 were used to evaluate their antiangiogenic effect by evaluating (Vascular endothelial growth Factor) VEGF expression and microvessels count. It was demonstrated that Anti-IL-8 mAb declined significantly the number of microvessels in the tumor tissues compared to Anti-IL-6 and the control tissue cultures p<0.0001. In addition, the decrease in the microvessels count was insignificant within the untreated normal tissues (p=0.46). Therefore, the antiangiogenic activity of Anti-IL-8 monoclonal antibody is more potent than Anti-IL-6 according to the study conditions.

Highlights

  • Breast cancer tumor microenvironment is a promising target for cancer immunotherapy.
  • IL-6 and IL-8 have a vital role in angiogenesis promotion in breast cancer.
  • Anti-IL-8 monoclonal antibody has a superior effect in angiogenesis inhibition compared to Anti-IL-6.

Keywords

Main Subjects

References

  1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23.
  2. Liu D, Wu J, Lin C, Andriani L, Ding S, Shen K, Zhu L. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Frontiers in oncology. 2020;10:580112.
  3. Li JJ, Tsang JY, Tse GM. Tumor microenvironment in breast cancer—updates on therapeutic implications and pathologic assessment. Cancers. 2021 Aug 23;13(16):4233.
  4. Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in breast cancer progression, diagnosis, and treatment. Journal of Cancer. 2020;11(15):4474.
  5. Ghalehbandi S, Yuzugulen J, Pranjol MZ, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. European Journal of Pharmacology. 2023;949:175586.
  6. David JM, Dominguez C, Hamilton DH, Palena C. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines. 2016 Jun 24;4(3):22.
  7. Abou Shousha SA, Hussein B, Shahine Y, Fadali G, Zohir M, Hamed Y, Hemedah M, Baheeg SA, Ibrahim A, El Shannawy M, Osman EM. Angiogenic activities of interleukin-8, vascular endothelial growth factor and matrix metalloproteinase-9 in breast cancer. Egypt J Immunol. 2022;29(3):54-63.
  8. Bao C, Zhou D, Zhu L, Qian W, Ye X. Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma. Translational Cancer Research. 2020;9(4):2378.
  9. Katongole P, Sande OJ, Nabweyambo S, Joloba M, Kajumbula H, Kalungi S, Reynolds SJ, Ssebambulidde K, Atuheirwe M, Orem J, Niyonzima N. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute. Future Oncology. 2022 Feb;18(6):661-7.
  10. Amer H, Kartikasari AE, Plebanski M. Elevated interleukin-6 levels in the circulation and peritoneal fluid of patients with ovarian cancer as a potential diagnostic biomarker: a systematic review and meta-analysis. Journal of Personalized Medicine. 2021 Dec 9;11(12):1335.
  11. Lin S, Gan Z, Han K, Yao Y, Min D. Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. Tumori Journal. 2015;101(5):535-41.
  12. Hegde M, Guruprasad KP, Ramachandra L, Satyamoorthy K, Joshi MB. Interleukin-6–mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors. Journal of Biological Chemistry. 2020;295(34):12086-98.
  13. Nasir A, Holzer TR, Chen M, Man MZ, Schade AE. Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies. Cancer cell international. 2017 ;17:1-2..
  14. Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE. Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Frontiers in pharmacology. 2022;13:838133.
  15. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer treatment reviews. 2020;86:102017.
  16. Hey SP, Gyawali B, D’Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises. JNCI: Journal of the National Cancer Institute. 2020;112(4):335-42.
  17. Abou Shousha S, Baheeg S, Ghoneim H, Zoheir M, Hemida M, Shahine Y. The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study). Breast Disease. 2023;42(1):163-76.
  18. Grosset AA, Loayza-Vega K, Adam-Granger É, Birlea M, Gilks B, Nguyen B, Soucy G, Tran-Thanh D, Albadine R, Trudel D. Hematoxylin and eosin counterstaining protocol for immunohistochemistry interpretation and diagnosis. Applied Immunohistochemistry & Molecular Morphology. 2019;27(7):558-63.
  19. Hofman F. Immunohistochemistry. Current protocols in immunology. 2002;49(1):21-4.
  20. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast cancer research and treatment. 1995;36:169-80.
  21. Singh SR, Rameshwar P, Siegel P. Targeting tumor microenvironment in cancer therapy. Cancer letters. 2016;380(1):203-4.
  22. Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S, Luo F, He J. The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Frontiers in immunology. 2022;13:802846.
  23. Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Medical Oncology. 2020;37:1-4.
  24. Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer treatment reviews. 2017;60:24-31.
  25. Abou Shousha S, Medhat E, Baheeg S, Shahine Y. Anti-IL-8 monoclonal antibodies inhibit the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment. Breast Disease. 2024;43(1):37-49.
  26. Ohsugi Y. The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicine. Journal of Translational Autoimmunity. 2020 ;3:100030.
  27. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H, Nishimura T. Anti‐IL‐6 receptor m A b eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses. European journal of immunology. 2012;42(8):2060-72.
  28. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. Journal of Thoracic Oncology. 2014;9(7):974-82.
  29. Wang D, Xu J, Liu B, He X, Zhou L, Hu X, Qiao F, Zhang A, Xu X, Zhang H, Wicha MS. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death & Differentiation. 2018;25(2):330-9.
  30. Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death & Disease. 2022;13(2):146.
  31. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nature Reviews Cancer. 2021;21(8):481-99.
  32. Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Frontiers in oncology. 2022;12:1023177.
  33. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22(10):1517-27.
  34. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2003;48(6):1521-9.
  35. Alraouji NN, Aboussekhra A. Tocilizumab inhibits IL‐8 and the proangiogenic potential of triple negative breast cancer cells. Molecular Carcinogenesis. 2021;60(1):51-9.
Journal of Advanced Pharmaceutical Sciences
Volume 2, Issue 1
January 2025
Pages 24-33

Files

Share

How to cite

Statistics